Pulseless ventricular tachycardia secondary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 24: Line 24:
[[Category:Cardiology]]
[[Category:Cardiology]]
[[Category:Cardiovascular diseases]]
[[Category:Cardiovascular diseases]]
[[Category:Inflammations]]
[[Category:Arrythmia]]
[[Category:Emergency medicine]]
[[Category:Emergency medicine]]
[[Category:Disease]]
[[Category:Disease]]

Latest revision as of 02:37, 18 May 2020

Pulseless ventricular tachycardia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pulseless ventricular tachycardia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography

Cardiac MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pulseless ventricular tachycardia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pulseless ventricular tachycardia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulseless ventricular tachycardia secondary prevention

CDC on Pulseless ventricular tachycardia secondary prevention

Pulseless ventricular tachycardia secondary prevention in the news

Blogs on Pulseless ventricular tachycardia secondary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Pulseless ventricular tachycardia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aisha Adigun, B.Sc., M.D.[2]

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include:

  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]

References


Template:WH Template:WS